Point of Care Creatinine Instruments Market Size by Product Type, Sample Type, End-User, And Geography

Point of Care Creatinine Instruments Market Size And Forecast

According to the publisher, the Global Point of Care Creatinine Instruments Market was valued at USD 602.26 Million in 2020 and is projected to reach USD 1,107.69 Million by 2027, growing at a CAGR of 9.10% from 2020 to 2027.

Global Point of Care Creatinine Instruments Market Overview

Point-of-care creatinine instruments facilitate early diagnosis of chronic kidney diseases (CKD) through screening programs, and by follow-up of kidney patients at high risk. Creatinine point-of-care (POC) analysis, especially the use of portable devices, enable fast diagnostic result in the homecare settings with the electronic medical record for the review of medical staff, which in turn, would allow management and diagnosis of serious conditions, like Haemolytic Uraemic Syndrome that can exist with repeated renal failures, which will provide a better prognosis of such conditions.

Global Point of Care Creatinine Instruments Market: Segmentation Analysis

The Global Point of Care Creatinine Instruments Market is segmented on the basis of Product Type, sample type, end-user, and geography.

Global Point of Care Creatinine Instruments Market Competitive Landscape

The Global Legal Process Outsourcing Market study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Abbott Diagnostics Inc., Nova Biomedical, Radiometer (The Danaher Corporation), Abaxis, Inc., Siemens AG, F. Hoffmann-La Roche Ltd., FUJIFILM Corporation, and Thermo Fisher Scientific Inc.